Skip to main content
SpringerLink
Log in

Early elevated alkaline phosphatase as a surrogate biomarker of ongoing metabolic bone disease of prematurity

  • RESEARCH
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Very low birth weight (VLBW) neonates present a high risk of metabolic bone disease (MBD). Our main objective was to determine the easiest way to make an early diagnosis of this disease by identifying surrogate biomarkers before any radiological signs occurred. We conducted in our NICU a 6-month observational prospective study, with inclusion of all singleton VLBW neonates. We collected clinical and biological data, and nutritional intakes during hospitalization. We defined biological MBD (bMBD) as alkaline phosphatase (ALP) levels superior to 600 UI/L at day of life 30 (DOL30) and performed a case–control analysis. Nine out of 30 patients (30%) exhibited bMBD. All have extremely low birth weight and were significantly younger in gestational age (GA) and smaller at birth. There was no statistically significant difference in nutritional intake between bMBD and control groups. In the bMBD group, phosphatemia was lower since DOL3. ALP was already significantly higher at DOL15, and way beyond normal range.

Conclusions: Our results showed that even the strict respect of nutritional guidelines cannot completely prevent bMBD in high-risk patients and suggest that an early screening from DOL15, with ALP levels greater than 500 UI/L, could be sufficient for detection of upcoming MBD.

What is Known:

• Metabolic bone disease of prematurity (MBD) definition is not consensual, but biological changes appear earlier than radiological signs of rickets.

• MBD management relies on biological evidence. Treatment is based on phosphate and/or calcium and calcitriol supplementation.

What is New:

• Studying phosphocalcic biological assessment in very low birth weight neonates, we showed respect of nutritional guidelines could not protect from biological MBD.

• Increase in alkaline phosphatase (ALP), about 500 UI/l at day of life 15, could be a biomarker of MBD with no need of X-ray evaluation and sufficient to begin a treatment to prevent osteopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Kovacs CS (2014) Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones. Physiol Rev 94:1143–1218

    Article  CAS  PubMed  Google Scholar 

  2. Kovacs CS (2015) Calcium, phosphorus, and bone metabolism in the fetus and newborn. Early Hum Dev 91:623–628

    Article  CAS  PubMed  Google Scholar 

  3. Rowe JC, Wood DH, Rowe DW, Raisz LG (1979) Nutritional hypophosphatemic rickets in a premature infant fed breast milk. N Engl J Med 300:293–296

    Article  CAS  PubMed  Google Scholar 

  4. Rowe JC, Wood DH, Rowe DW, Raisz LG (1979) Hypophosphatemic rickets and breast milk. N Engl J Med 300:1397–1398

    Article  CAS  PubMed  Google Scholar 

  5. Chinoy A, Mughal MZ, Padidela R (2019) Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. Arch Dis Child Fetal Neonatal Ed 104:F560–F566

    Article  PubMed  Google Scholar 

  6. Rayannavar A, Calabria AC (2020) Screening for metabolic bone disease of prematurity. Semin Fetal Neonatal Med 25:101086

    Article  PubMed  Google Scholar 

  7. Chacham S, Pasi R, Chegondi M, Ahmad N, Mohanty SB (2020) Metabolic bone disease in premature neonates: an unmet challenge. J Clin Res Pediatr Endocrinol 12:332–339

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rustico SE, Calabria AC, Garber SJ (2014) Metabolic bone disease of prematurity. J Clin Transl Endocrinol 1:85–91

    PubMed  PubMed Central  Google Scholar 

  9. Ziegler EE, O’Donnell AM, Nelson SE, Fomon SJ (1976) Body composition of the reference fetus. Growth 40:329–341

    CAS  PubMed  Google Scholar 

  10. Mihatsch W et al (2018) ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: calcium, phosphorus and magnesium. Clin Nutr Edinb Scotl 37:2360–2365

    Article  CAS  Google Scholar 

  11. Faienza MF et al (2019) Metabolic bone disease of prematurity: diagnosis and management. Front Pediatr 7:143

    Article  PubMed  PubMed Central  Google Scholar 

  12. Figueras-Aloy J et al (2014) Metabolic bone disease and bone mineral density in very preterm infants. J Pediatr 164:499–504

    Article  CAS  PubMed  Google Scholar 

  13. Mihatsch WA et al (2018) ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition. Clin Nutr Edinb Scotl 37:2303–2305

    Article  Google Scholar 

  14. Agostoni C et al (2010) Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 50:85–91

    Article  CAS  PubMed  Google Scholar 

  15. Fetal Growth Restriction (2021) ACOG Practice Bulletin, Number 227. Obstet Gynecol 137:e16

    Article  Google Scholar 

  16. Fenton TR (2003) A new growth chart for preterm babies: Babson and Benda’s chart updated with recent data and a new format. BMC Pediatr 3:13

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hung Y-L et al (2011) Serial measurements of serum alkaline phosphatase for early prediction of osteopaenia in preterm infants. J Paediatr Child Health 47:134–139

    Article  PubMed  Google Scholar 

  18. Viswanathan S et al (2014) Metabolic bone disease: a continued challenge in extremely low birth weight infants. JPEN J Parenter Enteral Nutr 38:982–990

    Article  PubMed  Google Scholar 

  19. Ukarapong S, Venkatarayappa SKB, Navarrete C, Berkovitz G (2017) Risk factors of metabolic bone disease of prematurity. Early Hum Dev 112:29–34

    Article  PubMed  Google Scholar 

  20. Zhang H et al (2021) Screening of serum alkaline ohosphatase and phosphate helps early detection of metabolic bone disease in extremely low birth weight infants. Front Pediatr 9:642158

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tinnion RJ, Embleton ND (2012) How to use... alkaline phosphatase in neonatology. Arch Dis Child Educ Pract Ed 97:157–163

  22. Faerk J, Peitersen B, Petersen S, Michaelsen KF (2002) Bone mineralisation in premature infants cannot be predicted from serum alkaline phosphatase or serum phosphate. Arch Dis Child Fetal Neonatal Ed 87:F133-136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Llorente-Pelayo S et al (2020) Modified serum ALP values and timing of apparition of knee epiphyseal ossification centers in preterm infants with cholestasis and risk of concomitant metabolic bone disease of prematurity. Nutrients 12:E3854

    Article  Google Scholar 

  24. Chinoy A, Mughal MZ, Padidela R (2021) Metabolic bone disease of prematurity—national survey of current neonatal and paediatric endocrine approaches. Acta Paediatr Oslo Nor 1992(110):1855–1862

    Article  Google Scholar 

  25. Kelly A, Kovatch KJ, Garber SJ (2014) Metabolic bone disease screening practices among U.S. neonatologists. Clin Pediatr (Phila.) 53:1077–1083

  26. Avila-Alvarez A et al (2020) Metabolic bone disease of prematurity: risk factors and associated short-term outcomes. Nutrients 12:E3786

    Article  Google Scholar 

  27. Backström MC et al (2000) Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Paediatr Oslo Nor 1992(89):867–873

    Article  Google Scholar 

  28. Fewtrell MS et al (2008) Quantitative ultrasound (QUS): a useful tool for monitoring bone health in preterm infants? Acta Paediatr Oslo Nor 1992(97):1625–1630

    Article  Google Scholar 

  29. Catache M, Leone CR (2003) Role of plasma and urinary calcium and phosphorus measurements in early detection of phosphorus deficiency in very low birthweight infants. Acta Paediatr Oslo Nor 1992(92):76–80

    Google Scholar 

  30. Lee J, Park H-K, Kim JH, Choi YY, Lee HJ (2017) Bone mineral density according to dual energy X-ray absorptiometry is associated with serial serum alkaline phosphatase level in extremely low birth weight infants at discharge. Pediatr Neonatol 58:251–257

    Article  PubMed  Google Scholar 

  31. de Lange A, Maaskant JM, van Weissenbruch MM (2021) Is quantitative ultrasound a measure for metabolic bone disease in preterm-born infants? A prospective subcohort study. Eur J Pediatr 180:3009–3017

    Article  PubMed  PubMed Central  Google Scholar 

  32. Tong L, Gopal-Kothandapani JS, Offiah AC (2018) Feasibility of quantitative ultrasonography for the detection of metabolic bone disease in preterm infants - systematic review. Pediatr Radiol 48:1537–1549

    Article  PubMed  PubMed Central  Google Scholar 

  33. Mitchell SM et al (2009) High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr 9:47

    Article  PubMed  PubMed Central  Google Scholar 

  34. Jensen EA et al (2016) Determinants of severe metabolic bone disease in very low-birth-weight infants with severe bronchopulmonary dysplasia admitted to a tertiary referral center. Am J Perinatol 33:107–113

    PubMed  Google Scholar 

  35. Chen W, Zhang Z, Dai S, Xu L (2021) Risk factors for metabolic bone disease among preterm infants less than 32 weeks gestation with bronchopulmonary dysplasia. BMC Pediatr 21:235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Visser F, Sprij AJ, Brus F (2012) The validity of biochemical markers in metabolic bone disease in preterm infants: a systematic review. Acta Paediatr Oslo Nor 1992(101):562–568

    Article  Google Scholar 

  37. Matejek T et al (2019) Parathyroid hormone — reference values and association with other bone metabolism markers in very low birth weight infants - pilot study. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet 32:2860–2867

  38. Czech-Kowalska J et al (2016) The clinical and biochemical predictors of bone mass in preterm infants. PLoS ONE 11:e0165727

    Article  PubMed  PubMed Central  Google Scholar 

  39. Moreira A et al (2014) Parathyroid hormone as a marker for metabolic bone disease of prematurity. J Perinatol Off J Calif Perinat Assoc 34:787–791

    CAS  Google Scholar 

  40. Tan Y-L, Tsao P-N, Chou H-C, Yen T-A, Chen C-Y (2021) Hypophosphatemia as an early metabolic bone disease marker in extremely low-birth-weight infants after prolonged parenteral nutrition exposure. JPEN J Parenter Enteral Nutr 45:1268–1274

    Article  CAS  PubMed  Google Scholar 

  41. Motokura K et al (2021) Appropriate phosphorus intake by parenteral nutrition prevents metabolic bone disease of prematurity in extremely low-birth-weight infants. JPEN J Parenter Enteral Nutr 45:1319–1326

    Article  CAS  PubMed  Google Scholar 

  42. Christmann V et al (2016) Changes in biochemical parameters of the calcium-phosphorus homeostasis in relation to nutritional intake in very-low-birth-weight infants. Nutrients 8:E764

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Poissy St Germain Hospital, Neonatal Intensive Care Unit, CHI Poissy-St Germain, 10 Rue du Champ Gaillard, 78300, Poissy, France

    Emmanuelle Motte-Signoret, Marwa Jlassi, Ludivine Lecoq, Pierre-Yves Wachter, Amélie Durandy & Pascal Boileau

  2. INRAE, BREED, Université Paris-Saclay, UVSQ, 78350, Jouy-en-Josas, France

    Emmanuelle Motte-Signoret

  3. Université Paris-Saclay, INSERM, Physiologie Et Physiopathologie Endocriniennes, 94276, Le Kremlin-Bicêtre, France

    Pascal Boileau

Authors
  1. Emmanuelle Motte-Signoret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwa Jlassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ludivine Lecoq
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre-Yves Wachter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amélie Durandy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pascal Boileau
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EMS, MJ, and PB conceived and designed the study. MJ, LL, PYW, AD, EMS, and PB provided clinical data. MJ and EMS analyzed the data. EMS and MJ drafted the article, and PB revised it critically for important intellectual content. All authors contributed to the writing and approval of the final version to be published.

Corresponding author

Correspondence to Emmanuelle Motte-Signoret.

Ethics declarations

Ethics approval

“French Advisory Committee for the Protection of People” and “Commission Nationale de l’Informatique et des Libertés” no. 2051804.

Consent to participate

Informed consent was obtained from legal guardians.

Competing interests

The authors declare no competing interests.

Additional information

Communicated by Daniele De Luca.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Motte-Signoret, E., Jlassi, M., Lecoq, L. et al. Early elevated alkaline phosphatase as a surrogate biomarker of ongoing metabolic bone disease of prematurity. Eur J Pediatr 182, 1829–1837 (2023). https://doi.org/10.1007/s00431-023-04839-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-023-04839-y

Keywords

Search

Navigation